Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus
With research facilities in the United States (New Jersey) and China (Shanghai, Suzhou, Nanjing, and Nantong), 1,000+ scientists, and over fifteen years of experience in Investigational New Drug (IND) application, our DMPK team at WuXi AppTec are serving 1,600+ global clients, and have successfully supported 1,500+ IND applications
Patients presented the largest weight loss reported to date with that drug class, prompting Novo Nordisk to conduct additional studies on semaglutide and other GLP-1Ra in people living with obesity (PwO) [18, 19]
Recognizing these signs is an important step toward getting evaluated
If you missed the other articles in the series, you can read them here: Part 1: How do GLP-1 medications like Wegovy, Ozempic, and Mounjaro work